CI

At a glance

ClinicalIndex Comparison Record
N/AUnknown· 120 target
Drug / intervention
Laparoscopic pancreatoduodenectomy +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04855331
NCT04855331N/AUnknown
CompareCT.gov

Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer: An Multicenter Open-label Randomized Clinical Trial

Fudan University·interventional·Posted Apr 22, 2021·Updated May 9, 2023

In Brief

A clinical study evaluating Laparoscopic pancreatoduodenectomy and Open pancreatoduodenectomy for Borderline Resectable Pancreatic Cancer. Targeting 120 participants across 1 site.

Detailed Summary

The aim of this study is to evaluate the safety and efficacy of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBorderline Resectable Pancreatic Cancer
CountriesChina
CollaboratorsThe Third Affiliated Hospital of Soochow University, Qilu Hospital of Shandong University, West China Hospital, Tongji Hospital, Fujian Provincial Hospital, Zhejiang Provincial People's Hospital

Timeline

N/AUnknownOverdue
20222023202420252026
First PostedApr 22, 2021
Enrollment StartApr 15, 2021
Primary CompletionDec 1, 2024
Study CompletionDec 1, 2025
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 5.2 years ago

Interventions

Laparoscopic pancreatoduodenectomyprocedure

Laparoscopic pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.

Open pancreatoduodenectomyprocedure

Open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.